Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 5
2010 4
2011 8
2012 8
2013 5
2014 12
2015 7
2016 9
2017 17
2018 20
2019 16
2020 18
2021 26
2022 22
2023 18
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Emiloju OE, et al. Among authors: borad mj. Invest New Drugs. 2024 Feb;42(1):127-135. doi: 10.1007/s10637-024-01420-8. Epub 2024 Jan 25. Invest New Drugs. 2024. PMID: 38270822 Clinical Trial.
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Pappas L, Baiev I, Reyes S, Bocobo AG, Jain A, Spencer K, Le TM, Rahma OE, Maurer J, Stanton J, Zhang K, De Armas AD, Deleon TT, Roth M, Peters MLB, Zhu AX, Boyhen K, VanCott C, Patel T, Roberts LR, Lindsey S, Horick N, Lennerz JK, Iafrate AJ, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Kelley RK, Goyal L. Pappas L, et al. Among authors: borad mj. JCO Precis Oncol. 2023 Aug;7:e2200594. doi: 10.1200/PO.22.00594. JCO Precis Oncol. 2023. PMID: 37561981 Free PMC article.
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Tella SH, et al. Among authors: borad mj. Oncologist. 2023 Oct 3;28(10):917-e966. doi: 10.1093/oncolo/oyad144. Oncologist. 2023. PMID: 37339254 Free PMC article. Clinical Trial.
Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
Desai AP, Kosari F, Disselhorst M, Yin J, Agahi A, Peikert T, Udell J, Johnson SH, Smadbeck J, Murphy S, Karagouga G, McCune A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield A. Desai AP, et al. Among authors: borad mj. J Immunother Cancer. 2023 Jun;11(6):e006035. doi: 10.1136/jitc-2022-006035. J Immunother Cancer. 2023. PMID: 37279993 Free PMC article. Clinical Trial.
Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer.
El Khoury LY, Lin WH, Smadbeck JB, Barrett MT, Sadeghian D, McCune AF, Karagouga G, Cheville JC, Harris FR, Kinsella LM, Feathers RW, Schafer Klein JL, Walther-Antonio MR, Johnson SH, Penheiter AR, Cucinella G, Schivardi G, Bhagwate A, Borad MJ, Mansfield AS, Murphy SJ, Mariani A, Vasmatzis G, Anastasiadis PZ, Weroha SJ, Larish AM. El Khoury LY, et al. Among authors: borad mj. Epigenomics. 2023 Mar;15(5):283-292. doi: 10.2217/epi-2023-0026. Epub 2023 May 22. Epigenomics. 2023. PMID: 37212177
168 results